Antibiotic resistance of helicobacter pylori from patients in Ile-Ife, South-west, Nigeria

African Health Sciences

Volumn 7, Issue 3, 2007, Pages 143-147

  Aboderin, Oladiipo A ^a   Abdu, Abdul R ^b   Odetoyin, Babatunde 'Wumi ^a   Okeke, Iruka N ^c   Lawal, Oladejo O ^a   Ndububa, Dennis A ^a   Agbakwuru, Augustine E ^a   Lamikanra, Adebayo ^a  

^a OBAFEMI AWOLOWO UNIVERSITY   (Nigeria)

^b NIGER DELTA UNIVERSITY   (Nigeria)

^c HAVERFORD COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BIOPSY; DRUG EFFECT; FEMALE; HELICOBACTER PYLORI; HUMAN; ISOLATION AND PURIFICATION; MALE; MIDDLE AGED; NIGERIA;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BIOPSY; DRUG RESISTANCE, BACTERIAL; FEMALE; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; NIGERIA;

EID: 45549083485     PISSN: 16806905     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Dunn BE, Cohen H, Blaser MJ. Helicobacter pylori. Clin Microbiol Rev. 1997:10:720-741.
2. Ernst PB, Gold BD. The disease spectrum of Helicobacter pylori: the immunopathogenesis of gastroduodenal ulcer and gastric cancer. Annu Rev Microbiol. 2000;54:615-640.
3. Malfertheiner P, Megraud F, O'Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G and European Helicobacter pylori Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Therap. 2002:16:167-180.
4. Gisbert JP, Pajares JM. Helicobacter pylori therapy: first line options and rescue regimen. Dig Dis. 2001:19:134-143
5. Malfertheiner, P., F. Megraud, C. O'Morain, F. Bazzoli, E. El-Omar, D. Graham, R. Hunt, T. Rokkas, N. Vakil, and E. J. Kuipers. 14 December 2006. Current concepts in the management of Helicobacter pylori infection- The Maastricht III Consensus Report. Gut. doi: 10.1136/gut.2006.101634.
6. Jenks PJ, Edwards DI. Metronidazole resistance in Helicobacter pylori. Int J Antimicrob Agents. 2002:19:1-7
7. Osato MS, Reddy R, Reddy SG, Penland RL, Malaty HM, Graham DY. Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States. Arch Intern Med. 2001:161:1217-1220.
8. Wu H, Shi XD, Wang HT, Liu JX. Resistance of Helicobacter pylori to metronidazole, tetracycline and amoxycillin. J Antimicrobial Chemother. 2000:46:121-123.
9. Kwon DH, Kim JJ, Lee M. et al. Isolation and characterization of tetracycline-resistant clinical isolates of Helicobacterpylor i. Antimicro Agents Chemother. 2000:44:3203-3205.
10. Dai G, Cheng N, Dong L. et al. Bactericidal and morphological effects of NE-2001, a novel synthetic agent directed against Helicobacter pylori. Antimicro Agents Chemother. 2005:49:3468-3473.
11. Lawal OO, Fadiran OA, Oluwole SF, Campbell B. Clinical pattern of prepyloric and duodenal ulcer at Ile-Ife, Nigeria. Trop Doct. 1998: 28(3):152-155.
12. Ndububa DA, Agbakwuru AE, Adebayo RA et al. Upper gastrointestinal findings and incidence of Helicobacter pylori infection among Nigerian patients with dyspepsia. West Afr J Med. 2001:20(2):140-145
13. Ogunbodede EO, Lawal OO, Lamikanra A, Okeke IN, Rotimi O, Rasheed AA. Helicobacter pylori in the dental plaque and gastric mucosa of dyspeptic Nigerian patients. Trop Gastroenterol. 2002:23(3):127-133.
14. Soltesz V, Zeeberg B, Wadstrom T. Optimal survival of Helicobacter pylori under various transport conditions. J Clin Microbiol. 1992 ;30(6):1453-1456.
15. th edition 1997 Lippincott pp 321-361
16. Lopez Brea M, Alarcon T: Sensibilidad antimicrobiana en la infeccion por Helicobacter pylori. En: Lopez Brea M. Helicobacter pylori microbiologia, clinica y tratamiento; Madrib; Morsby/Doyma Libros. 1995;32-53.
17. National Committee for Clinical Laboratory Standards. Approved Standard M7-A5: Methods/or Dilution Antimicrobial Susceptibility Tests/or Bacteria That Grow Aerobically (National Committee for Clinical laboratory Standards, Wayne, PA) 2000.
18. 1 Graham DY. Antibiotic resistance in Helicobacter pylori: implications for therapy. Gastroenterol. 1998:115:1272-1277.
19. Okeke IN, Fayinka ST, Lamikanra A. Antibiotic resistance in Escherichia coli from Nigerian students, 1986-1998. Emerg Infect Dis. 2000: 6(4): 393-396
20. Okeke IN, Lamikanra A, Edelman R. Socioeconomic and behavioral factors leading to acquired bacterial resistance to antibiotics in developing countries. Emerg. Infect Dis. 1999: 5(1): 18-27.
21. McMahon BJ, Hennessy TD, Bensler JM et al. The relationship among antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann Int Med . 2003:139:463-469.
22. Pilotto A, Rassu M, Leandro G et al. Prevalence of Helicobacter pylori resistance to antibiotics in Northeast Italy: a multicentre study. GISU. Interdisciplinary Group for the Study of Ulcer. Dig Liver Dis 2000:32:763-768
23. Megraud F. H. pylori antibiotic resistance: prevalence, importance and advances in testing. Gut. 2004:53:1374-1384.
24. Torres J, Camorlinga-Ponce M, Perez-Perez G et al. Increasing multidrug resistance in Helicobacter pylori strains isolated from children and adults in Mexico. J Clin Microbiol. 2001:39:2677-2680.
25. Glupczynski Y, Megraud F, Lopez-Brea M, Anderson LP. European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Euro J Clin Mirobiol Infect Dis. 2000:11:820-823.
26. Quintana-Guzman EM, Arias-Echandi ML, Salas-Chaves P, Davidovich-Rose H, Schosinsky-Neverman K: Helicobacter pylori: susceptibility to amoxycillin, erythromycin, tetracycline, ciprofloxacin, nitrofurantoin and metronidazole in Costa Rica. Rev Biomed. 1998: 9:92-96
27. Graham DY, Hepps KS, Ramirez FC, Lew GM, Saeed ZA. Treatment of Helicobacter pylori reduces the rate of re-bleeding in peptic ulcer disease. Scand J Gastroenterol. 1993: 28:939-942.
28. Kato S, Fujimura S, Udagawa H, et al. Antibiotic resistance of Helicobacter pylori strains in Japanese children. J Clin Microbiol. 2002: 40:649-653.
29. Xia HX, Buckley M, Keane Ct, O'Morain CA: Clarithromycin resistance in Helicobacter pylori: prevalence in untreated dyspeptic patients and stability in vitro. J Antimicroibial Chemother. 1996: 37:473-481.
30. Midolo PD, Korman MG, Turnidge JD, Lambart JR. Helicobacter pylori resistance to tetracycline. Lancet. 1996; 347: 1194-1195.
31. Piccolomini R, Bonaventura GD, Catamo G, Carbone F, Neri M. Comparative evaluation of the E test, agar dilution, and broth dilution for testing susceptibilities of Helicobacter pylori to 20 antimicrobial agents. J Clin Microbiol. 1997: 135:1842-1846.
32. Dore MP, Piana A, Carta M, et al. Amoxycillin resistance is one reason for failure of amoxycillin-omeprazole treatment of Helicobacter pylori infection. Aliment Pharmacol Therap. 1998: 12:635-639.
33. Dore MP, Sepulveda AR, Mura I, Realdi G, Osato MS and Graham DY. Explanation for variability of omeprazole amoxycillin therapy? Tolerance of H. pylori to amoxicillin. Gastroenterol. 1997: 112: A105 (Abstract).
34. Cabrita J, Oleastro M, Matos R, et al. Features and trends in Helicobacter pylori antibiotic resistance in Lisborn area, Portugal (1990-1999). J Antmicrob Chemother. 2000: 46(6):1029-1031.